Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Cipla
Mallinckrodt
Federal Trade Commission
US Army
Teva
Harvard Business School
McKinsey
US Department of Justice

Generated: May 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,754,070

« Back to Dashboard

Summary for Patent: 8,754,070
Title:Testosterone gel and method of use
Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.
Inventor(s): Malladi; Ramana (Marietta, GA), Stahlman; Jodi (Smyrna, GA)
Assignee: Unimed Pharmaceuticals, LLC (Marietta, GA) Besins Healthcare Luxembourg SARL (Charlotte, LU)
Application Number:13/831,217
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,754,070
Patent Claims: 1. A gel pharmaceutical composition consisting of: a) 1.62% (w/w) testosterone; b) 1.0% (w/w) isopropyl myristate; c) 68.1% (w/w) absolute ethanol; and d) 1.0% (w/w) of a gelling agent, which gelling agent is an anionic polymer that has been neutralized with an amount of neutralizer sufficient to form a gel; and e) water.

2. The gel pharmaceutical composition of claim 1, wherein the anionic polymer is a polyacrylic acid.

3. The gel pharmaceutical composition of claim 1, wherein the anionic polymer is a carbomer.

4. The gel pharmaceutical composition of claim 1, wherein the neutralizer is selected from the group consisting of: sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethyl propanol, tetrahydroxypropyl ethylenediamine, triethanolamine, tromethamine, PEG-15 cocamine, diisopropanolamine and triisopropanolamine and combinations thereof.

5. The gel pharmaceutical composition of claim 4, wherein the neutralizer is sodium hydroxide.

6. The gel pharmaceutical composition of claim 1, which consists of: a) 1.62% (w/w) testosterone; b) 1.0% (w/w) isopropyl myristate; c) 68.1% (w/w) absolute ethanol; and d) 1.0% (w/w) of a carbomer which has been neutralized with sodium hydroxide; and e) water.

7. The gel pharmaceutical composition of claim 1, which consists of: a) 1.62% (w/w) testosterone; b) 1.0% (w/w) isopropyl myristate; c) 68.1% (w/w) absolute ethanol; and d) 1.0% (w/w) of a carbomer; e) an amount of sodium hydroxide sufficient to form a gel; and f) water.

8. The gel pharmaceutical composition of claim 1, wherein a therapeutically effective dose of the gel pharmaceutical composition for treatment of hypogonadism in a human male comprises 40.5 milligrams of testosterone.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
Accenture
US Army
Mallinckrodt
Daiichi Sankyo
Federal Trade Commission
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.